Navigating an Increasingly Complex Treatment Landscape in the Management of Hepatocellular Carcinoma (HCC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer, Bristol-Myers Squibb, Eisai, Exelixis, and Merck Sharp & Dohme Corp

Description:
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. In 2019, it was expected that liver cancer accounted for approximately 788,000 deaths globally, making it the second leading cause of cancer-related deaths worldwide. The prevalence and mortality rate of liver cancer has been rising steadily over the past decade. This year, approximately 42,030 people in the United States will be diagnosed and 31,780 will die from their disease. Liver cancer is still on the rise and death rates are increasing faster than any other type of cancer. Prognosis is especially poor for those with unresectable HCC. Fortunately for patients with HCC, new agents have become available in the last few years, including targeted therapy. They have shown the ability to improve safety and efficacy outcomes, especially in patients with disease progression. However, with each new treatment, medical directors, oncologists, nurses and other healthcare professionals must stay abreast of the underlying mechanisms, current data, and treatment-emergent adverse events to provide their patients with optimal care. The amount of information surrounding emerging treatments for HCC can be daunting; this conference session will provide these healthcare professionals with a much-needed, concise overview of the available data and strategies.

For the treatment of HCC, transplantation is an option for patients, however, there is a limited supply of good-quality deceased donor organs. Thus, other treatments, including systemic therapy, should be used to bridge patients to transplant or to delay recurrence if possible in unresectable HCC. Fortunately, clinicians have been equipped with new individualized options recently, including targeted therapies, which provide options for the unmet need of treatment in HCC, especially beyond first-line therapy. Tyrosine kinase inhibitors (TKIs) have shown improved efficacy and safety in HCC, and healthcare professionals must be educated on these options, how they should be integrated into the treatment paradigm, and the potential risks that come along with any treatment option.

As novel targeted therapy options have become available for patients with HCC, medical directors, practicing oncologists, nurses and other healthcare professionals providing care for patients with HCC are struggling to stay abreast of these advances, especially as it relates to therapy beyond the first line.

Upon completion of this activity, participants will be able to:

  • Describe the mechanistic rationales underlying recent targeted and immunotherapeutic drug development in HCC and how they relate to HCC biology

  • Explore the role of tyrosine kinase inhibitors (TKIs) in the management of unresectable HCC

  • Examine the evolving role of immunotherapy and targeted therapy combination regimens in the management of HCC based on recent clinical trial data

  • Implement strategies for optimally sequencing treatment, alone or in combination, for patients with unresectable HCC

  • Identify patients with unresectable advanced HCC for whom a targeted agent or immunotherapeutic agent is an appropriate choice for the next step in the management of their cancer

  • Analyze effective strategies to monitor and manage the unique adverse events associated with targeted therapies and immunotherapies in advanced HCC
     

Faculty: Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
Vice-Chair and Section Lead, Division of Medical Oncology
Senior Associate Consultant, Mayo Clinic AZ

Disclosure:

Dr. Bekaii-Saab serves as a consultant for Array, Armo, AstraZeneca, Bayer, Exelixis, Ipsen, Isofol, Merck, and Silajen. He has received grant/research support from Abgenomics, Array Biopharma, Arrys, Bayer, BMS, Boston Biomedical, Clovis, Genentech, Incyte, Ipsen, Merck, Pfizer, and Seattle Genetics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grant from
Bayer, Bristol-Myers Squibb, Eisai, Exelixis, and Merck Sharp & Dohme Corp

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue